RxSight, Inc. (NASDAQ:RXST – Get Free Report) insider Ilya Goldshleger sold 3,105 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $46.08, for a total transaction of $143,078.40. Following the sale, the insider now owns 42,246 shares in the company, valued at $1,946,695.68. The trade was a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Ilya Goldshleger also recently made the following trade(s):
- On Friday, November 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $45.00, for a total transaction of $139,500.00.
- On Tuesday, November 26th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $45.88, for a total transaction of $142,228.00.
- On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The stock was sold at an average price of $46.00, for a total transaction of $224,250.00.
- On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $45.00, for a total value of $139,500.00.
- On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The shares were sold at an average price of $46.13, for a total value of $61,352.90.
- On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $51.91, for a total value of $161,180.55.
- On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total value of $154,349.00.
- On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total transaction of $156,984.00.
- On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total transaction of $154,008.00.
- On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total value of $155,529.45.
RxSight Stock Performance
Shares of NASDAQ:RXST traded down $2.28 on Tuesday, hitting $43.56. 536,829 shares of the company were exchanged, compared to its average volume of 487,154. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of -52.48 and a beta of 1.11. The company’s 50 day moving average price is $48.47 and its two-hundred day moving average price is $52.06. RxSight, Inc. has a one year low of $29.97 and a one year high of $66.54.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
RXST has been the topic of several research analyst reports. Wells Fargo & Company cut their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus reduced their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Jefferies Financial Group initiated coverage on RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. Finally, Oppenheimer lowered their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research report on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $61.63.
RxSight Company Profile
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Recommended Stories
- Five stocks we like better than RxSight
- Quiet Period Expirations Explained
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- Business Services Stocks Investing
- Netflix Is On Track To Hit $1,000 By Christmas
- 5 Top Rated Dividend Stocks to Consider
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.